Harvard-born diabetes startup Semma reports advances in turning stem cells into insulin...

cafead

Administrator
Staff member
  • cafead   May 10, 2019 at 10:32: AM
via Semma Therapeutics has faced an obstacle with its process of turning undifferentiated pluripotent stem cells into insulin-producing pancreatic beta cells: Only 30% of the resulting cells turn out to be beta cells. Now, a Semma-Harvard University team has figured out how to boost the proportion of beta cells emerging from their process to 80%.

article source
 

<